ReviewCurrent pharmaceutical design2017
Cannabis Epidemiology: A Selective Review.
Review in Current pharmaceutical design, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis.JAMA network open · 2020Pooled it
- Relationship Between Cannabis Use and Erectile Dysfunction: A Systematic Review and Meta-Analysis.American journal of men's healthPooled it
- A pilot randomized controlled trial of dialectical behavior therapy (DBT) for reducing craving and achieving cessation in patients with marijuana use disorder: feasibility, acceptability, and appropriateness.Trends in psychiatry and psychotherapyTrial
- Chronic THC Inhalation During Early Adulthood Exacerbates Ovariectomy-Induced Bone Loss in a Rat Model of Osteoporosis.Biomedicines · 2026Article
- Article
- Cannabis use patterns and different phenotypes in relation to other drugs use: latent class analyses from the Sao Paulo Megacity Mental Health Survey.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025Article
- Role of Point-of-Care Gastric Ultrasound in Advancing Perioperative Fasting Guidelines.Diagnostics (Basel, Switzerland) · 2024Review
- Patterns of Use and Withdrawal Syndrome in Dual Cannabis and Tobacco Users (DuCATA_GAM-CAT): Protocol for a Mixed Methods Study.JMIR research protocols · 2024Article
- Depressive symptoms predict cannabis vaping initiation among young adults.Drug and alcohol dependence · 2024Article
- Lifetime use of alcohol and cannabis among U.S. adolescents across age: Exploring differential patterns by sex and race/ethnicity using the 2019 NSDUH data.Drug and alcohol dependence reports · 2024Article
- Association of cannabis use with depression among cancer patients.Preventive medicine reports · 2023Article
- Cannabis Use and Sharing Practices Among Sexual Minority and Heterosexual Individuals During the COVID-19 Pandemic.LGBT health · 2023Article
- Cannabis use and gastrointestinal tract illnesses: The National Health and Nutrition Examination Surveys, 2005-2018.Drug and alcohol review · 2023Article
- Patterns of Cannabis- and Substance-Related Congenital General Anomalies in Europe: A Geospatiotemporal and Causal Inferential Study.Pediatric reports · 2023Article
- Current state of cannabis use, policies, and research across sixteen countries: cross-country comparisons and international perspectives.Trends in psychiatry and psychotherapy · 2022Article
- Review
- Lower Rates of Hepatocellular Carcinoma Observed Among Cannabis Users: A Population-Based Study.Cureus · 2022Article
- The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real-world Clinical Setting.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Using the Theory of Reasoned Action to examine grandparent and maternal substance use on the cannabis use of children of teen mothers.Drug and alcohol dependence · 2021Article
- Tobacco cigarette and cannabis use among new mothers.Addiction (Abingdon, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundGlobally, the most widely used set of compounds among the internationally regulated drugs is cannabis.
objectiveTo review evidence from epidemiological research on cannabis, organized in relation to this field's five main rubrics: quantity, location, causes, mechanisms, and prevention/ control.
methodThe review covers a selection of evidence from standardized population surveys, official statistics, and governmental reports, as well as published articles and books identified via MEDLINE, Web of Science, and Google Scholar as of July 2016.
resultsIn relation to quantity, an estimated 3% to 5% of the world population is thought to have tried a cannabis product, with at least one fairly recent use, mainly extra-medical and outside boundaries of prescribed use. Among cannabis users in the United States, roughly one in 7-8 has engaged in medical marijuana use. In relation to location, prevalence proportions reveal important variations across countries and between subgroups within countries. Regarding causes and mechanisms of starting to use cannabis, there is no compelling integrative and replicable conceptual model or theoretical formulation. Most studies of mechanisms have focused upon a 'gateway sequence' and person-to-person diffusion, with some recent work on disability-adjusted life years. A brief review of cannabis use consequences, as well as prevention and control strategies is also provided.
conclusionAt present, we know much about the frequency and occurrence of cannabis use, with too little replicable definitive evidence with respect to the other main rubrics. Given a changing regulatory environment for cannabis products, new institutions such as an independent International Cannabis Products Safety Commission may be required to produce evidence required to weigh benefits versus costs. It is not clear that governmentsponsored research will be sufficient to meet consumer demand for balanced points of view and truly definitive evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.